Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

The 64-week trial is comparing Novartis’ drug with the current formulation of Eylea, while last year the FDA approved a 12 ... in the wet AMD market is off-label use of Roche’s VEGF inhibitor ...

and is the first ophthalmology biosimilar to be registered by the FDA. The approval comes a few weeks after the biosimilar was cleared for marketing in the EU with a broader label, as it also ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...

The FDA is the federal agency that oversees the "safety, nutritional adequacy, packaging, and labeling" of infant formula products, according to its website. When an infant formula is brought to ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

The Food and Drug Administration (FDA) announced Tuesday it will be moving to take ingestible prescription fluoride products for children off the market, citing concerns that the mineral alters ...

Stacey Leasca is an award-winning journalist with nearly two decades of newsroom experience. She is also the co-founder of Be a Travel Writer, an online course for the next generation of travel ...

The head of the U.S. Food and Drug Administration (FDA) is sounding the alarm on a ... prescribed or dispensed and have even revised the labels to warn people of its potential addiction.

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...